Neurological Disorder Drugs Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Neurological Disorder Drugs Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.
A neurological disorder is a medical condition associated with the nervous system, resulting in physical or psychological symptoms. Neurological disorders can be congenital, which emerge during the early years of embryo developmental and may be diagnosed at birth. Whereas, some of the acquired neurological disorders develop after the birth due to brain injuries, immune disorders, postnatal injections, spinal cord injuries, neoplasm, and exposure to environmental chemicals or toxins, and other factors.
Get Your FREE Sample Copy of the Neurological Disorder Drugs Market Report 2021
Many bacterial (Mycobacterial tuberculosis, Neisseria meningitides), viral (Human Immunodeficiency Virus (HIV), Enteroviruses, West Nile Virus, Zika), fungal (Cryptococcus, Aspergillus), and parasitic (malaria, Chagas) infections can also affect the nervous system, which can result into neurological disorders.
Antipsychotic, antiepileptic, anticholinergic, and analgesics are some of the neurological drugs that are used for the treatment. These drugs help in managing the neurological condition and reduce symptoms. Moreover, corticosteroids are the most popular drug used in the treatment of multiple sclerosis and assist in reducing inflammation.
Neurological Disorder Drugs Market: Drivers
Growing awareness regarding the early disease diagnosis through awareness campaigns by government regulatory bodies and private organizations and the introduction of efficient drugs is projected to fuel the growth of the neurological disorder drugs market.
Buy Now This Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/2363
Reasons to Purchase this Report
• Current and future of global Neurological Disorder Drugs market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/2363
For instance, according to a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA) in April 2018, there are currently 537 medicines in development by biopharmaceutical companies in the U.S for various neurological disorders. This mainly includes 95 medicines for brain tumors, 46 for chronic pain, and 92 for Alzheimer’s disease. The other 30 are being developed for a range of conditions including multiple sclerosis, migraines, amyotrophic lateral sclerosis, and Parkinson’s disease.
Furthermore, key players are engaged in gaining regulatory approval for neurological drugs, to expand its market presence. For instance, in April 2017, the U.S. Food and Drug Administration (FDA) approved Neurocrine Biosciences’ Ingrezza (valbenazine), the first drug to treat tardive dyskinesia in adults.
Furthermore, UCB S.A., a Belgium-based company involved in the research and development of anti-epileptic drugs (AEDs), received European Commission (EC) approval for BRIVIACT (brivaracetam) as an adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalization in adult and adolescent patients from 16 years of age with epilepsy.
Neurological Disorder Drugs Market: Restraint
On the other hand, stringent and lengthy drug approval procedures, strict policies in prescribing sedatives for the treatment of neurological disorders, and a slowdown in the production of drugs, owing to expensive research and development cost is projected to hamper the global neurological disorder drugs market growth over the forecast period.
Ask for PDF sample copy of the Neurological Disorder Drugs market report @ https://www.coherentmarketinsights.com/insight/request-pdf/2363
Neurological Disorder Drugs Market: Regional Analysis
North America is expected to hold a dominant position in the global neurological disorder drugs market and account for the largest market share over the forecast period, and this can be attributed to the strong presence of key players in the region and rapid approval and launch of novel products by them in the region.
For instance, in May 2018, Amgen received the U.S. FDA approval for Aimovig (erenumab-more), for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach and the only FDA-approved treatment specifically developed to prevent migraines by blocking the calcitonin gene-related peptide receptor (CGRP-R), which plays a critical role in migraine.
Neurological Disorder Drugs Market: Key Players
Key players operating in the global neurological disorder drugs market include Amgen Inc., UCB S.A., Neurocrine Biosciences, Inc., Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., AcelRx Pharmaceuticals, Inc., Eli Lilly and Company, Ionis Pharmaceuticals, Inc., Adamas Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Otsuka America Pharmaceutical, Inc., AstraZeneca plc, and Novartis International AG.
Neurological Disorder Drugs Market: Taxonomy
The global neurological disorder drugs market is segmented based on drug type, disease type, distribution channel, and region.
By Drug Type
- Antipsychotic
- Antiepileptic
- Anticholinergic
- Analgesics
- Hypnotic & Sedative
- Anticoagulants
- Antihypertensive
By Disease Type
- Epilepsy
- Parkinson’s disease
- Alzheimer’s disease
- Cerebrovascular disease
- Multiple Sclerosis
- Others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Major Point Answered in Neurological Disorder Drugs Market Research Study are: –
• What will the market growth rate, Overview, and Analysis by Type of Neurological Disorder Drugs market in 2026?
• What are the key factors driving, Analysis by Applications and Countries Neurological Disorder Drugs market?
• What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Manufacturers Profiles of Neurological Disorder Drugs market?
• Who are the Opportunities, Risk, and Driving Force of Neurological Disorder Drugs market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in the Neurological Disorder Drugs market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Neurological Disorder Drugs market opportunities and threats faced by the vendors in the market?
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837